NCI-Designated Cancer Center at Sanford Burnham Prebys

One of only seven National Cancer Institute-designated Basic Laboratory Cancer Centers in the nation.
Cancer Center researchers

Taking aim at cancer

“Our Cancer Center is committed to performing impactful translational multi-disciplinary research that addresses unmet clinical needs relevant to the diagnosis and treatment of cancer.”

– Ze'ev Ronai, Ph.D., Center Director

Director's Statement

 

Achieving our goals through collaboration

Our scientists are always looking for novel ideas, partners and new ways of doing groundbreaking research to target cancer.

Programs

Tumor Initiation and Maintenance Program

Understanding the cells that give rise to tumors and the signals allowing them to expand uncontrollably will help us learn how to defeat cancer.

Learn More

Cell and Molecular Biology of Cancer Program

Insights into the complex system of networks and mechanisms that tumors use to survive and proliferate will lead us to tumor-specific, less toxic therapies.

Learn More

Aging, Cancer and Immuno-oncology Program

We are studying the interplay among cancer cells, immune cells and their environment to put the brakes on cancer.
 

Learn More

Latest news

Publications

PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.

Kim H, Kim H, Feng Y, Li Y, Tamiya H, Tocci S, Ronai ZA

Sci Transl Med 2020 Jul 8 ;12(551)

Inhibition of Nuclear Pore Complex Formation Selectively Induces Cancer Cell Death.

Sakuma S, Raices M, Borlido J, Guglielmi V, Zhu EYS, D'Angelo MA

Cancer Discov 2021 Jan ;11(1):176-193

Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells.

Galenkamp KMO, Sosicka P, Jung M, Recouvreux MV, Zhang Y, Moldenhauer MR, Brandi G, Freeze HH, Commisso C

Cancer Discov 2020 Jun ;10(6):822-835

Induction of the activating transcription factor-4 in the intratumoral CD8+ T cells sustains their viability and anti-tumor activities.

Lu Z, Bae EA, Verginadis II, Zhang H, Cho C, McBrearty N, George SS, Diehl JA, Koumenis C, Bradley LM, Fuchs SY

Cancer Immunol Immunother 2022 Sep 5 ;

"A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression".

Tzaridis T, Weller J, Bachurski D, Shakeri F, Schaub C, Hau P, Buness A, Schlegel U, Steinbach JP, Seidel C, Goldbrunner R, Schäfer N, Wechsler-Reya RJ, Hallek M, Scheffler B, Glas M, Haeberle L, Herrlinger U, Coch C, Reiners KS, Hartmann G

Int J Cancer 2022 Aug 27 ;

Origin of cytoplasmic GDP-fucose determines its contribution to glycosylation reactions.

Sosicka P, Ng BG, Pepi LE, Shajahan A, Wong M, Scott DA, Matsumoto K, Xia ZJ, Lebrilla CB, Haltiwanger RS, Azadi P, Freeze HH

J Cell Biol 2022 Oct 3 ;221(10)

NRF2 mediates melanoma addiction to GCDH by modulating apoptotic signalling.

Verma S, Crawford D, Khateb A, Feng Y, Sergienko E, Pathria G, Ma CT, Olson SH, Scott D, Murad R, Ruppin E, Jackson M, Ronai ZA

Nat Cell Biol 2022 Sep 1 ;

Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios.

Verano AL, You I, Donovan KA, Mageed N, Yue H, Nowak RP, Fischer ES, Wang ES, Gray NS

ACS Chem Biol 2022 Aug 25 ;

Subgroup-Enriched Pathways and Kinase Signatures in Medulloblastoma Patient-Derived Xenografts.

Leskoske KL, Garcia-Mansfield K, Sharma R, Krishnan A, Rusert JM, Mesirov JP, Wechsler-Reya RJ, Pirrotte P

J Proteome Res 2022 Sep 2 ;21(9):2124-2136

Show All Publications